These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 21218459)
1. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Mattiuzzi GN; Cortes JE; Blamble DA; Bekele BN; Xiao L; Cabanillas M; Borthakur G; O'Brien S; Kantarjian H Cancer; 2010 Dec; 116(24):5659-66. PubMed ID: 21218459 [TBL] [Abstract][Full Text] [Related]
2. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Gralla R; Lichinitser M; Van Der Vegt S; Sleeboom H; Mezger J; Peschel C; Tonini G; Labianca R; Macciocchi A; Aapro M Ann Oncol; 2003 Oct; 14(10):1570-7. PubMed ID: 14504060 [TBL] [Abstract][Full Text] [Related]
3. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220 [TBL] [Abstract][Full Text] [Related]
4. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415 [TBL] [Abstract][Full Text] [Related]
5. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Aapro MS; Grunberg SM; Manikhas GM; Olivares G; Suarez T; Tjulandin SA; Bertoli LF; Yunus F; Morrica B; Lordick F; Macciocchi A Ann Oncol; 2006 Sep; 17(9):1441-9. PubMed ID: 16766588 [TBL] [Abstract][Full Text] [Related]
6. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. Kovács G; Wachtel AE; Basharova EV; Spinelli T; Nicolas P; Kabickova E Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844 [TBL] [Abstract][Full Text] [Related]
7. Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese". Di Renzo N; Melillo L; Porretto F; Dargenio M; Pavone V; Pastore D; Mazza P; Mannina D; Merenda A; Cascavilla N; Greco G; Matera R; Bonizzoni E; Celio L; Musso M Cancer Med; 2020 Jan; 9(1):170-178. PubMed ID: 31725196 [TBL] [Abstract][Full Text] [Related]
8. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Nakagaki M; Barras M; Curley C; Butler JP; Kennedy GA Support Care Cancer; 2017 Feb; 25(2):607-613. PubMed ID: 27738796 [TBL] [Abstract][Full Text] [Related]
9. Palonosetron: in the prevention of nausea and vomiting. Yang LP; Scott LJ Drugs; 2009 Nov; 69(16):2257-78. PubMed ID: 19852528 [TBL] [Abstract][Full Text] [Related]
10. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Rubenstein EB Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194 [TBL] [Abstract][Full Text] [Related]
11. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients. Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N; Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891 [TBL] [Abstract][Full Text] [Related]
12. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. Rozzi A; Nardoni C; Corona M; Restuccia MR; Fabi A; Bria E; Minniti G; Lanzetta G Support Care Cancer; 2011 May; 19(5):697-701. PubMed ID: 20467757 [TBL] [Abstract][Full Text] [Related]
14. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735 [TBL] [Abstract][Full Text] [Related]
15. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119 [TBL] [Abstract][Full Text] [Related]
16. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S; Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083 [TBL] [Abstract][Full Text] [Related]
17. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991 [TBL] [Abstract][Full Text] [Related]
18. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Aapro M; Fabi A; Nolè F; Medici M; Steger G; Bachmann C; Roncoroni S; Roila F Ann Oncol; 2010 May; 21(5):1083-8. PubMed ID: 20080830 [TBL] [Abstract][Full Text] [Related]
19. Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Noor R; Bedikian AY; Mahoney S; Bassett R; Kim K; Papadopoulos N; Hwu WJ; Hwu P; Homsi J Support Care Cancer; 2012 Oct; 20(10):2583-8. PubMed ID: 22274951 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]